Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Background: For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19 CAR-T cells may be ineffective due to anti-mouse single-chain variable fragment (scFv) antibody caused by mCD19 CAR. To overcome t...

Full description

Bibliographic Details
Main Authors: An, L. (Author), Chang, A.H (Author), Deng, B. (Author), Lin, Y. (Author), Ling, Z. (Author), Liu, S. (Author), Tong, C. (Author), Wu, T. (Author), Yin, Z. (Author), Zhao, D. (Author), Zhao, Y. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
acute lymphoblastic leukemia
Acute lymphoblastic leukemia
adoptive immunotherapy
adult
Adult
adverse event
animal
Animals
Antigens, CD19
Burkitt lymphoma
Burkitt Lymphoma
CD19 antigen
child
Child
Chimeric antigen receptor-T
genetics
human
Humans
Immunotherapy, Adoptive
Mice
mouse
Precursor Cell Lymphoblastic Leukemia-Lymphoma
procedures
Receptors, Chimeric Antigen
Relapsed/refractory
single chain fragment variable antibody
Single-Chain Antibodies
Single-chain variable fragment
T lymphocyte
T-Lymphocytes
World Health Organization
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items